Brigham and Women's Hospital investigators link very high lipoprotein(a) with a higher 30-year risk of major cardiovascular ...

Currently available therapies such as niacin and PCSK9 inhibitors such as Repatha (evolocumab) and Praluent (alirocumab) can reduce Lp (a) levels, but their impact is modest. Another challenge in ...

A nearly 30-year study shows a strong long-term association between very high lipoprotein(a) levels and cardiovascular ...

Very high Lp(a) also correlated with higher risks of ischemic stroke and cardiovascular mortality in the Women’s Health Study ...

A new study finds that elevated levels of Lp(a) may increase the risk of death from cardiovascular disease in some patie ...

Elevated levels of lipoprotein (a) is a genetic disease that causes cardiovascular disease. Steven Nissen, M.D., addresses why it’s important to find treatments for this genetic risk factor.

Comparing extremes of the spectrum, multivariable analyses generally showed significantly higher risks for patients with high ...

As part of "heart health month," we're looking at lipoprotein (a). For decades, doctors have encouraged patients to monitor their cholesterol levels, with studies showing that heart disease risk ...

Low-density lipoprotein, known as LDL, is a complex structure with several components that allow cholesterol to circulate in the bloodstream, a watery environment. LDL is the primary mechanism used to ...

Lipoprotein(a), a fatty particle, can clog arteries just as surely as cholesterol but often goes undetected, striking seemingly healthy people unaware of the danger.

Every Australian adult should be screened for a potentially deadly type of inherited cholesterol, and if the simple blood ...